ESC 365 - Rationale for a new furosemide product 50 years after its first introduction.

HFA Premium Access

Rationale for a new furosemide product 50 years after its first introduction.

Session: Furosemide 2.0 - Subcutaneous administration of a novel formulation

Topic: Acute Heart Failure

Speaker: Professor R. De Boer (Rotterdam, NL)

Sponsored by scPharmaceuticals, Inc.

Event: Heart Failure 2017 - 4th World Congress on Acute Heart Failure

Congress Presentation

Add to my library

About the speaker

Professor Rudolf De Boer

Erasmus University Medical Centre, Rotterdam (Netherlands (The))

60 presentations

8 followers

3 more presentations in this session

Health policy and economics related to treatment of fluid overload in heart failure.

Speaker: Doctor N. Desai (New Haven, US)

Clinical experience with subcutaneous furosemide in patients with fluid overload.

Speaker: Doctor N. Gilotra

First experience with a patch infusor for subcutaneous administration of a novel furosemide formulation.

Speaker: Professor J. Udelson (Boston, US)

Access the full session

Furosemide 2.0 - Subcutaneous administration of a novel formulation

Speakers: Professor R. De Boer, Doctor N. Desai, Doctor N. Gilotra, Professor J. Udelson

About the event

Heart Failure 2017 - 4th World Congress on Acute Heart Failure

29 April - 2 May 2017

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources

Explore sponsored resources